Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 17Terminated 5Recruiting 4Active not recruiting 3Unknown 1

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3

Conditions

Leukemia, Myeloid, Acute 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Myelodysplastic Syndromes 10Burkitt Lymphoma 9Lymphoma, Mantle-Cell 6Leukemia, Biphenotypic, Acute 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Lymphoma 4Leukemia 4Recurrence 3Myeloproliferative Disorders 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myelomonocytic, Chronic 3Down Syndrome 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Follicular 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Monocytic, Acute 2Blast Crisis 2Vasculitis, Central Nervous System 1Stiff-Person Syndrome 1Rasmussen subacute encephalitis 1Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1Plasmablastic Lymphoma 1Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1Pathologic Complete Response 1Opsoclonus-Myoclonus Syndrome 1Neuromyelitis Optica 1Neoplasms 1

Interventions

Cyclophosphamide 7fludarabine 6Whole-Body Irradiation 6Tacrolimus 6Mycophenolic Acid 6ruxolitinib 5fludarabine phosphate 5Melphalan 5venetoclax 4Peripheral Blood Stem Cell Transplantation 4itacitinib 3Specimen Handling 3Sirolimus 3Granulocyte Colony-Stimulating Factor 3Cytarabine 3Biopsy 3Azacitidine 3navitoclax 2luspatercept 2Etoposide 2Daunorubicin 2Busulfan 2Antilymphocyte Serum 2thymoglobulin 1selinexor 1quizartinib 1pomalidomide 1plerixafor 1pevonedistat 1parsaclisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Myeloproliferative Disorders × Cytarabine × Clear all
NCT06034470 2026-05-07

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Fred Hutchinson Cancer Center

Phase 1 Active not recruiting
30 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

NCT04802161 2025-12-19

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

National Cancer Institute (NCI)

Phase 2 Active not recruiting
50 enrolled 12 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02521493 2025-08-01

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Children's Oncology Group

Phase 3 Active not recruiting
280 enrolled 13 charts
MyeloidOther hematologic neoplasm

Down Syndrome, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡